ado-trastuzumab emtansine

Overview

Ado-trastuzumab emtansine, also known as T-DM1, is an antibody-drug conjugate used in HER2-directed cancer therapy. It combines trastuzumab, a monoclonal antibody that targets the extracellular domain of the Erb-b2 receptor tyrosine kinase 2 (HER2), with the cytotoxic microtubule inhibitor emtansine (DM1). By binding HER2-positive tumor cells and delivering the payload intracellularly, it is designed to provide targeted antitumor activity while limiting systemic exposure compared with conventional chemotherapy.

In biomedical research, ado-trastuzumab emtansine is most often studied in HER2-positive breast cancer and other HER2-altered solid tumors. Its role is closely tied to treatment sequencing with other HER2-directed agents, including trastuzumab-pertuzumab and trastuzumab deruxtecan, and to combination strategies intended to improve response rates or overcome resistance.

Focus of Latest Publications

Recent publications on ado-trastuzumab emtansine (T-DM1) have focused on its role in HER2-targeted treatment strategies, safety characterization, and formulation-related considerations. In HER2-positive early breast cancer, the PHERGain-2 study evaluated a chemotherapy-free, pathological response-adapted approach using trastuzumab-pertuzumab with T-DM1, specifically testing a pCR-guided de-escalation strategy to omit chemotherapy in selected patients. In HER2-positive metastatic breast cancer, real-world work examined antibody-drug conjugate sequencing, comparing outcomes with trastuzumab deruxtecan in patients with and without prior T-DM1 exposure, reflecting ongoing uncertainty about optimal sequencing of HER2-directed ADCs.

Other recent studies assessed T-DM1 in combination regimens and in safety surveillance settings. A phase Ia/Ib trial investigated mobocertinib plus T-DM1 in patients with HER2-mutant solid tumors, evaluating the safety and efficacy of combining a HER2 tyrosine kinase inhibitor with an anti-HER2 antibody-drug conjugate. Separately, pharmacovigilance analyses compared adverse event profiles of trastuzumab emtansine and trastuzumab deruxtecan using the Japanese Adverse Drug Event Report database and the U.S. FDA Adverse Event Reporting System, aiming to better characterize the incompletely defined safety profile of HER2-targeting antibody-drug conjugates.

Beyond clinical use, T-DM1 also appeared in studies relevant to biotherapeutic development and analytical characterization. One machine learning and experimental study of IgG1 and IgG4 self-association included clinical-stage antibodies and linked self-association behavior to viscosity and concentration performance, with acidic formulations containing proline identified as effective at suppressing self-association. Another study on imaged capillary isoelectric focusing examined how amino acid excipients can affect charge heterogeneity measurements of monoclonal antibodies, highlighting formulation-dependent analytical interference that is relevant to protein therapeutics such as T-DM1.

Key Publications

NEWJan Adverse Event Profiling and Comparative Analysis of HER2-targeting Antibody-drug Conjugates Using Pharmacovigilance Databases. (In vivo (Athens, Greece), 2026, PMID 42379740): "Therefore, we compared the adverse events for trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) using the Japanese Adverse Drug Event Report (JADER) database and U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)."
May Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties. (mAbs, 2026, PMID 42100922): "Here, we experimentally profile the self-association behavior of a panel of clinical-stage antibodies as a function of pH, excipient content, and antibody isotype."
Jun A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study. (Annals of oncology : official journal of the European Society for Medical Oncology, 2026, PMID 42097893): "A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study."
May Impact of Amino Acid Excipients on icIEF Method Development in Protein Therapeutics: A Formulation-Aware Analytical Framework. (AAPS PharmSciTech, 2026, PMID 42091782): "Using a six-pI marker ladder and two representative mAbs (Immunoglobulin-G1: IgG1 and Immunoglobulin-G4: IgG4), our findings demonstrated that amino acids with pI values outside the analyte's focusing region..."
Jun Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure. (Breast (Edinburgh, Scotland), 2026, PMID 41980521): "Optimal sequencing of trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer (mBC) remains uncertain, and real-world evidence on the impact of prior T-DM1 exposure on subsequent T-DXd outcomes is limited."
May Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M). (European journal of cancer (Oxford, England : 1990), 2026, PMID 41903301): "We here evaluated the safety and efficacy of the HER2-TKI mobocertinib together with the anti-HER2 ADC trastuzumab emtansine (T-DM1) in a phase I study."